China NMPA Launches Online Platform for Non-Clinical Drug Safety Evaluation Institutions
Streamlining GLP lab compliance for drug development in China.
The platform was launched on October 16, 2025.
NMPA | Pharmaceuticals | Country Regulatory AffairsSaudi FDA Issues Final Guideline on Economic Evaluation Studies (EES) for Medicinal Products
Better healthcare decisions through pharmacoeconomics
The final guideline came into effect on October 21, 2025.
SFDA | Pharmaceuticals | Country Regulatory AffairsNotice of Temporary Narcotics Designation – South Korea
Stay informed on MFDS South Korea’s latest notice (No. 2025-433) announcing the temporary designation of six new substances as narcotics, including Fluetonitazen, due to their potential risks to public health.
The notice was issued on October 20, 2025.
MFDS | Pharmaceuticals | Country Regulatory AffairsGuidelines for the Evaluation of Dendritic Cell Therapy for Cancer Treatment – South Korea
Stay informed on MFDS South Korea’s latest guideline (Guide-0298-02) outlining Regulatory, quality, and clinical considerations for dendritic cell therapies in cancer treatment.
The guideline was issued on October 20, 2025.
MFDS | Pharmaceuticals | Country Regulatory AffairsTGA Updates Sponsor Information Dashboard (SID) for GMP Clearance Applications
Track backlog reduction, processing times, and prioritization strategies for GMP clearance applications in Australia.
Effective from October 7, 2025
TGA | Pharmaceuticals | Country Regulatory Affairs
Consult
